Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will be available in 10 provinces and one territory for the fall 2026-2027 respiratory seasonA protein-based, non-mRNA vaccine that has demonstrated high efficacy
ScionxBio (the "company", operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA
Sanofi to work with provinces, territories, and federal drug programs to support patient access through public drug plansTORONTO, Oct. 15, 2026 /CNW/ -- Sanofi today announced the successful completion of negotiations
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was
The six-time NBA All-Star, three-time All-NBA selection, 2016 NBA Rookie of the Year, and 2026 NBA Champion Karl-Anthony Towns brings his personal experience with COVID-19 to encourage eligible people, especially those
The $925 million (CAD) expansion is adding end-to-end vaccine manufacturing capacity on Canadian soilBuilt in partnership with the Government of Canada, the Province of Ontario, and the City of Toronto to bolster the
Despite their risk of serious illness from COVID-19, nearly 70% of adults 65 and older remain unvaccinated, in part due to concerns about potential side effectsThe campaign serves up COVID-19 prevention education,
AUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") drugs on the market today can slow the disease down, but none of them stop it, and none of them give
Emmy Award-winning actress, entrepreneur and mom Keke Palmer partners with Sanofi to help educate families about protection against a serious respiratory syncytial virus (RSV) lung infectionBEYFORTUS has been chosen by
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9
Expansion to create 50 new high-skilled jobs in AI and reinforce Sanofi's long-term commitment to OntarioInvest Ontario Fund to contribute a conditional grant of up to $5 millionPartnership with the Province of
Nuvaxovid, a non-mRNA COVID-19 vaccine, will be made available in Canada by Sanofi for the fall 2026-2027 seasonProvincial and territorial availability will be confirmed pending ongoing discussions and provincial
CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the
Three provinces now cover Rezurock® (belumosudil) through their provincial formularies for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (GVHD) after failure of at least two
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Dynavax Technologies Corporation (NASDAQ:DVAX) to Sanofi
